JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms
JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.
Economy · News reference
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’
CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?
Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs.
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.
Lam Research Could Swing $28.6 Billion After Earnings
Discover 9 stocks with the biggest options-implied earnings moves, led by Spotify at 9.31%, as investors prepare for key quarterly results.
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight
The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.